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Abstract
IKKe and TBK1 are noncanonical IKK family members which regulate inflammatory signaling pathways and also play
important roles in oncogenesis. However, few inhibitors of these kinases have been identified. While the substrate
specificity of IKKe has recently been described, the substrate specificity of TBK1 is unknown, hindering the development of
high-throughput screening technologies for inhibitor identification. Here, we describe the optimal substrate
phosphorylation motif for TBK1, and show that it is identical to the phosphorylation motif previously described for IKKe.
This information enabled the design of an optimal TBK1/IKKe substrate peptide amenable to high-throughput screening
and we assayed a 6,006 compound library that included 4,727 kinase-focused compounds to discover in vitro inhibitors of
TBK1 and IKKe. 227 compounds in this library inhibited TBK1 at a concentration of 10 mM, while 57 compounds inhibited
IKKe. Together, these data describe a new high-throughput screening assay which will facilitate the discovery of small
molecule TBK1/IKKe inhibitors possessing therapeutic potential for both inflammatory diseases and cancer.
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Introduction
The IKK family of kinases consists of four family members, the
canonical IKKa and IKKb, as well as two noncanonical family
members, IKKe and TBK1. Together, this family of kinases
regulates a myriad of critical cellular processes including in-
flammation, survival, proliferation, senescence, and autophagy [1–
4]. Consistent with these numerous functions, aberrant IKK
signaling can result in susceptibility to diseases such as in-
flammatory disorders and cancer [1,3,5,6]. The canonical IKK
complex, which consists of IKKa, IKKb, and a regulatory
subunit, NEMO, is a point of convergence for a variety of stimuli.
Upon activation, the canonical IKKs, primarily IKKb, phosphor-
ylate IkBa, the inhibitor of NF-kB, which promotes the
ubiquitination and degradation of IkBa [3,7,8]. The transcription
factor NF-kB is then freed to accumulate in the nucleus and
activate the transcription of a number of target genes involved in
inflammatory and stress responses [3,7,8].
In contrast to the canonical IKKs, IKKe and TBK1 are
activated by a smaller subset of inflammatory stimuli, and are
especially critical for antiviral responses [6,7,9]. These kinases
phosphorylate and activate the transcription factors IRF3, IRF7,
and STAT1, promoting a Type 1 interferon response [10–14].
These kinases also activate NF-kB, but the mechanism by which
this occurs in unclear since they do not phosphorylate both of the
serines on IkBa which are required for IkBa degradation [15,16].
IKKe and TBK1 can also promote oncogenesis. For example,
IKKe is overexpressed in some breast and ovarian cancers, and
TBK1 was recently shown to be important for Ras-induced cell
transformation [17–20]. In spite of the important role these kinases
play in both inflammatory and oncogenic signaling, few inhibitors
have been identified. BX-795, a small molecule inhibitor of 3-
phosphoinositide-dependent protein kinase 1 (PDK1), inhibits
both IKKe and TBK1 at low nanomolar concentrations in vitro
(IC50 at 41 nM and 6 nM, respectively) [21,22]. However, BX-
795 lacks selectivity as 16 out of 76 tested kinases were inhibited by
BX-795 in the nM range [21]. It was also recently shown that
a series of azabenzimidazole derivatives inhibits these kinases in
the low nM range, but 6 of 79 kinases tested using one of these
compounds were inhibited in a range within 10-fold of TBK [23].
These results suggest that IKKe and TBK1 are suitable targets for
small molecule inhibitor development, but the need for the
development of selective inhibitors of IKKe and TBK1 remains.
The development of high throughput assays to identify
inhibitors of TBK1 and IKKe was hindered until recently by
the absence of information regarding the substrate specificities of
these enzymes. Peptide substrates for IKKe and TBK1 are
frequently based on the IKKb phosphorylation sites in IkBa, even
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41494though there is no evidence that all IKK family members
phosphorylate the same substrate repertoires. In fact, the recently
published phosphorylation motifs for IKKa, IKKb and IKKe
suggest that these kinases do have overlapping, but quite different,
optimal peptide substrates, although a detailed comparison of the
ability of IKK family members to phosphorylate these different
peptide substrates has not been performed [24–26]. The
phosphorylation motif for TBK1 has not been previously reported.
Here, a positional scanning peptide library (PSPL) technology
was used to determine the optimal phosphorylation motif for
TBK1. We demonstrate that the substrate specificity of TBK1 is
identical to that of IKKe, but differs from the phosphorylation
motif of IKKb at key positions. Importantly, we also demonstrate
that, like IKKe, TBK1 phosphorylates its predicted optimal
peptide (TBK1-Tide) more efficiently than an optimal peptide for
IKKb or a peptide containing the IKKb phosphorylation sites
present in IkBa. We then used this information to develop and
validate an IKKe/TBK1 peptide substrate appropriate for high-
throughput chemical screening and executed a high-throughput
screen (HTS) against both TBK and IKKe.
Results
While it is clear that misregulation of TBK1 activity can promote
inflammatorydisordersandmayplayaroleinoncogenesis,theroleof
TBK1inthesesignalingpathwaysispoorlyunderstood.Determining
thesubstratespecificityofTBK1,therefore,wouldfacilitateboththe
prediction of novel TBK1 substrates and the development of high-
throughputassaystoidentifyeffectiveTBK1inhibitors.Tothisend,
we utilized PSPL technology to determine the optimal TBK1
phosphorylation motif using GST-TBK1 purified from HEK293T
cells [27,28]. This technology employs 198 biotinylated peptide
libraries, which are used as substrates in individual solution-based
kinase assays. Each peptide library has a mixture of serine and
threonine at a fixed central position and also has one other position
fixed to one of the 20 naturally-occurring amino acids. Phospho-
threonine and phosphotyrosine were also included at the fixed
positions to allow the identification of primed phosphorylation
events. All other positions contain a degenerate mixture of amino
acids. Following a kinase reaction, the biotinylated peptides are
captured with an avidin membrane and preferences for individual
aminoacidsateachpositioncanbeexaminedviatheincorporationof
radiolabeled phosphate. This PSPL assay revealed that TBK1 has
preferences at a number of positions relative to the phosphorylation
site,whileakinase-deadGST-TBK1K38Adoesnot(Figures1A-B).
TBK1hasanabsoluterequirementforahydrophobicresidueatthe
+1position relative to the phosphorylation site (Figures 1A,1C, and
S1). TBK1 also displays a strong preference for phenylalanine or
tyrosine at the -2 position, and a minor preference for bulky
hydrophobicresiduesatthe+3position(Figures1A,1C,andFigure
S1). To confirm this phosphorylation motif, an optimal peptide
(TBK1-Tide) was generated and was efficiently phosphorylated by
TBK1 in vitro. In contrast, peptides in which the +1 leucine or -2
tyrosinearechangedtoalaninewerenolongerefficientlyphosphor-
ylated by TBK1(Figure 1D).
TBK1 is highly homologous to the related kinase IKKe, and
also shares significant homology with the canonical IKK family
member IKKb. The substrate specificities of IKKe, IKKa, and
IKKb have also recently been determined using the PSPL
technology [24–26]. Not surprisingly, the phosphorylation motif
for TBK1 is identical to that of IKKe. Interestingly, while both the
noncanonical and canonical IKKs display preferences for hydro-
phobic residues at the +1 position and aromatic residues at the -2
position, the optimal phosphorylation motifs for these kinases
differ at other positions. For example, while TBK1 prefers large
aliphatic residues at the +3 position, IKKa and IKKb prefer
acidic residues at +3. In addition, the canonical IKKs display
a strong preference for phosphorylated residues at the -4 and -5
positions, suggesting that these kinases can be primed by upstream
phosphorylation events. However, no evidence of priming
phosphorylation is observed for TBK1. Consistent with these
data, a peptide substrate corresponding to the well-established
IKKa/b phosphorylation sites on IkBa was phosphorylated by
TBK1 much less efficiently than TBK1-Tide (Figure 1D).
As the PSPL assays employ degenerate peptide mixtures, it was
important to confirm differences in the substrate specificities
among the IKKs using individual peptide substrates. To this end,
the predicted optimal IKKb substrate peptide (IKKb-Tide-pT)
was generated [25]. This peptide contains the +1 leucine and -2
tyrosine which are preferred by all IKK family members, but
differs from TBK1-Tide at secondary positions. Importantly, this
peptide contains a phosphothreonine residue at -4. We also
generated a similar peptide (IKKb-Tide-A) which is identical to
IKKb-Tide-pT except that it contains an alanine at the -4
position. All four IKK family members were then examined for
their ability to phosphorylate TBK1-Tide, IKKb-Tide-pT, and
IKKb-Tide-A. Indeed, Figures 2A-B show that TBK1 and IKKe
strongly prefer to phosphorylate their optimal peptide, TBK1-
Tide. Importantly, they also show no significant preference for
IKKb-Tide-pT over IKKb-Tide-A, confirming that these kinases
cannot be primed by upstream phosphorylation events. In
contrast, IKKa and IKKb strongly prefer to phosphorylate the
optimal IKKb substrate peptide, IKKb-Tide-pT, over either
TBK1-Tide or IKKb-Tide-A, demonstrating their preference for
the optimal IKKa/b substrate peptide and their ability to be
primed by upstream phosphorylation events (Figures 2C-D). These
data clearly show the importance of secondary and tertiary
selections for the IKKs to properly identify their substrates. In
addition, these data suggest that while TBK1 and IKKe may share
a significant number of substrates, the canonical and noncanonical
IKKs are likely to have somewhat overlapping, yet distinct,
substrate pools.
As few small molecule inhibitors of IKK family members with
clinical potential have been identified, the development of effective
screening technologies to identify novel inhibitors of IKK family
members is of great interest. To validate that phosphorylation of
TBK1-Tide can be blocked by a known TBK1/IKKe inhibitor,
purified GST-TBK1 or GST-IKKe was incubated with 50 mM
TBK1-Tide and increasing concentrations of a known TBK1/
IKKe inhibitor, BX-795, for 20 minutes. An in vitro kinase reaction
was then initiated by addition of c
32P-ATP, and incorporation of
radiolabeled ATP was measured (Figure 3A-B). Indeed, phos-
phorylation of TBK1-Tide provides an effective read-out for the
measurement of TBK1 and IKKe activity (Figure 3A-B).
This validated substrate specificity was then used to develop
assays for TBK1 and IKKe which are compatible with HTS using
microfluidic capillary electrophoresis (MCE). MCE operates on
the principle that small fluorescently-labeled peptide substrates
from ,100 nanoliter sized aliquots of reaction samples are
separable in a capillary channel etched in a quartz microfluidic
chip ratio when a current is applied [29,30]. This technique has
been widely adopted as a gold standard assay in the profiling of
small molecule inhibitors of kinases and can be tested in a high-
throughput fashion [31,32]. TBK1-Tide was synthesized with an
N-terminal 5– Carboxyfluorescein (5-FAM) dye for use as
a substrate. The TBK1-Tide synthesized for HTS (5-FAM-Aha-
ADADYASLDWDA-NH2) retained all of the residues critical for
phosphorylation by TBK1 and IKKe, but had the -1 and -4 Asp
Identification of TBK1 and IKKe Inhibitors
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isomerization. TBK1 and IKKe were characterized for their
behavior with this substrate and found to have Km values for ATP
of 7.5 mM and 4.7 mM respectively (Figure 4A-B). Because of the
MCE system’s limits of detection, TBK1-Tide was fixed at
a concentration of 1 mM and Km values for substrate were not
determined. The enzyme concentrations were then titrated and
fixed to 120 nM for TBK1 and 81 nM for IKKe. These values
were chosen to give 30% conversion of substrate to product after 2
hours of incubation (data not shown).
Compounds were screened at a final concentration of 10 mMi n
0.1% DMSO. Two libraries of compounds were tested. The
Library of Pharmaceutically Active Compounds (LOPAC) consists
of 1280 known bioactive small molecules, including 300 FDA
approved drugs including antibiotics, and compounds targeting
gene regulation and expression, multi-drug resistance, apoptosis,
ion channels, neurotransmission, calcium signaling, lipid signaling
and phosphorylation regulation. This library was tested in
duplicate to establish the reproducibility of the screen (Figure
S2). A second kinase-focused library consisting of 4,727 unique
and ‘‘rule of five’’ compliant compounds was also tested
(Figures 5A and B) [33].
Results from the HTS were found to follow a quasi-normal
distribution (Figures 5A and B) [34]. Compounds that showed
inhibition values greater than three standard deviations from the
mean value (50% inhibition for TBK1 and 30% for IKKe) were
consideredactive.Activecompoundsfromeachtargetwereclustered
based on structural similarity using Pipeline Pilot software [35] and
filteredfordrug-likepropertiesusingtheREOSfilter(Table1)[36].
Activecompoundsfromthekinasecassettethatshowedselectivityfor
either enzyme were re-tested in 10 point dose response curves to
establish potency values. This screen demonstrated that 227
compounds in the library inhibited TBK1 at a concentration of
10 mM and 57 compounds inhibited IKKe at a concentration of
10 mM (Figure 6). The structures of the five most active compounds
are shown in Figure 7, including 4 TBK1-specific inhibitors and 1
dualTBK1/IKKeinhibitor.Allofthesecompoundsinhibitedthese
kinases atconcentrations ofless than 1 mM.
As IKKb and IKKa are closely related to TBK1 and IKKe,i t
was important to determine the specificity of any candidate
inhibitors. A secondary screen was therefore performed to evaluate
the ability of the top-scoring TBK1 and IKKe inhibitors to inhibit
the canonical IKKs. It was determined that IKKb phosphorylated
TBK1-Tide efficiently enough to perform this secondary screen,
though for IKKa the commercially available Caliper FL-1 peptide
was more efficiently phosphorylated than TBK1-Tide (data not
shown). The ATP Km of IKKb for TBK1-Tide was 2 mM and the
ATP Km of IKKa for FL-1 was 134 mM (Figure S3). Enzyme
concentrations were titrated and fixed to 11.5 mM for IKKa and
1.1 mM for IKKb and the screen was performed as described
above for TBK1 and IKKe. Importantly, few of the compounds
which inhibited TBK1 or IKKe also inhibited IKKa or IKKb,
Figure 1. Identification of the optimal phosphorylation motif for TBK1. A-B) The positional scanning peptide library technology was used to
determine the optimal phosphorylation motif for recombinant A) GST-TBK1 WT or B) kinase-dead GST-TBK1 K38A as described previously [27,28].
Briefly, 198 peptide libraries were phosphorylated in individual kinase assays. The sequence for these libraries is Y-A-X-X-X-Z-X-S/T-X-X-X-X-A-G-K-K-
biotin (Z= fixed amino acid, X= equimolar mixture of amino acids excluding Ser, Thr, and Cys). After binding to a streptavidin-coated membrane,
phosphorylation was visualized by the incorporation of
32P. C) Primary and secondary selections for TBK1, as determined in A). D) 50 mM of the
indicated peptide was phosphorylated in an in vitro kinase assay with recombinant GST-TBK1 for 30 min. Phosphorylation of each peptide is shown
as a percentage of the rate of phosphorylation of TBK1-Tide, the optimal peptide substrate for TBK1. Error bars are standard deviation.
doi:10.1371/journal.pone.0041494.g001
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effective against IKKa and IKKb (Figures 6, 7 and Table S1).
Together, these data confirm that the inhibitors identified in this
screen are specific for TBK1 or TBK1/IKKe among the IKK
family members.
Discussion
The development of effective small-molecule screening tech-
nologies for kinases is dependent on appropriately measuring
changes in enzyme activity. While phosphorylation of a known
protein substrate can be measured as a reporter for kinase activity,
Figure 2. Members of the IKK family have different optimal peptide substrates. Recombinant GST-IKKa, GST-IKKb, GST-IKKe, and GST-TBK1
were overexpressed in and purified from HEK293T cells. Each IKK family member was incubated in an in vitro kinase assay with 50 mM TBK1-Tide,
IKKb-Tide-pT, or IKKb-Tide-A at 30uC for 45 min. TBK1-Tide = ADADYASLDWDAKK. IKKb-Tide-pT = ADpTRYESIDEEAKKK. IKKb-Tide-A =
ADARYESIDEEAKKK. Phosphorylation of each peptide was measured for A) TBK1 B) IKKe C) IKKa and D) IKKb. Error bars are standard deviation.
doi:10.1371/journal.pone.0041494.g002
Figure 3. Inhibitor efficacy can be measured via phosphorylation of TBK1-Tide. A-B) Mixtures of A) TBK1 or B) IKKe with 50 mM TBK1-Tide
were incubated with increasing concentrations of BX-795 for 20 minutes at RT. In vitro kinase reactions were then initiated with addition of c
32-P-ATP
to a final concentration of 100 mM, and incubated at 30uC for 30 minutes. Error bars are standard deviation.
doi:10.1371/journal.pone.0041494.g003
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large, consistent quantities, and is more amenable to the de-
velopment of non-radioactive assays. However, the generation of
an optimal peptide substrate requires a thorough understanding of
kinase substrate specificity, and this information is only available
for a small fraction of the .500 protein kinases in the human
genome. The substrate specificities of three IKK family members,
IKKa, IKKb and IKKe, have recently been described [24–26].
Like IKKe, TBK1 is a noncanonical IKK family member
which regulates Type I interferon signaling and may play a role in
oncogenesis. Here, a positional scanning peptide library technol-
ogy was utilized to identify the optimal phosphorylation motif for
TBK1 (Figure 1) [27]. The substrate specificity of TBK1 is
Figure 4. ATP Km determination for TBK1 and IKKe. Enzymatic reactions of A) TBK1 or B) IKKe were incubated at room temperature with 10 ATP
concentrations varying from 333 mM to 0.017 mM in three fold dilutions. Reactions were sampled on the Caliper EZReader system at 9.35 minute
intervals over a 3 hour period. Percent conversions were calculated from relative heights of product and substrate peaks and used to calculate
velocity and ATP Km in Graph Pad Prism.
doi:10.1371/journal.pone.0041494.g004
Figure 5. Distribution of compound activity. A–B) The kinase library was screened at 10 mM in a single concentration format against enzymatic
reactions of A) TBK1 and B) IKKe. The distribution of activity is shown as a frequency histogram based on the number of compounds active at each
level (% Inhibition). The data follow a normal distribution.
doi:10.1371/journal.pone.0041494.g005
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specificities of the noncanonical IKKs share overlapping char-
acteristics with the substrate specificity of the canonical IKKs, but
the optimal peptide substrates for these kinases are quite different
(Figure 2). These data allowed the generation of a peptide
substrate for TBK1 and IKKe (TBK1-Tide) which is amenable to
high-throughput screening. This technology was then used to
screen the LOPAC library and a kinase-focused library to discover
in vitro inhibitors of TBK1 and IKKe. This HTS revealed that 227
compounds in this library inhibited TBK1 at a concentration of
10 mM and 57 compounds inhibited IKKe, including several
compounds that inhibited these enzymes at sub-micromolar
concentrations (Figure 7). Of the compounds tested in this screen,
the molecules in the LOPAC library were of particular interest
since this library contains known bioactive molecules. The best
TBK1/IKKe inhibitors from the LOPAC library are therefore
shown in Table S1. Unfortuntately, none of the compounds from
the LOPAC library were among the best inhibitors of IKKe or
TBK1, and many lacked specificity as they also inhibited IKKa
(Table S1). Studies examining the ability of the compounds in
Figure 7 to inhibit TBK1 or IKKe in cell-based assays are
ongoing. As TBK1 and IKKe are points of convergence for both
inflammatory and oncogenic signaling pathways, the further
refinement of novel TBK1/IKKe inhibitors may provide powerful
new therapeutic drugs for inflammatory disorders or cancer.
Materials and Methods
Antibodies, Plasmids, and Reagents
GST-TBK1 was created by PCR cloning into the BamHI site of
the pEBG vector. GST-TBK1 K38A was created using a modi-
fication of the QuickChange Site-directed mutagenesis protocol
(Stratagene). GST-IKKe, GST-IKKa, and GST-IKKb for in vitro
kinase assays were generated and used as previously reported [24–
26]. TBK1-Tide (ADDDYDSLDWDAKKK), TBK1-Y5A (AD-
DDADSLDWDAKKK), and TBK1-L8A (ADDDYDSADW-
DAKKK) used in Figure 1 were created and HPLC purified
under contract by the Tufts University Core Facility. The TBK1
peptide used in Figures 2 and 3 (ADADYASLDWDAKK) was
generated to decrease the likelihood of Asp isomerization observed
Table 1. Activity comparison for TBK1 and IKKe.
TBK1 IKKe
Nunfiltered hits =227 (@ inh..50%) Nunfiltered hits =5 7( @i n h . .30%)
Nfiltered.drug-like =184 Nfiltered.drug-like =33
NLOPAC =18 N LOPAC =12
NKinase lib =166 NKinase lib =21
Nclusters =11(N in cluster $3) Nclusters =0(N in cluster $3)
Nsingletons =105 Nsingletons =27
Number of active compounds (N) detected in each screen for total number
detected (unfiltered), number after drug like filtering (filtered.drug-like), hits
from the LOPAC and Kinase libraries, and the number of chemical clusters and
singleton hits as described in the text.
doi:10.1371/journal.pone.0041494.t001
Figure 6. Relative activity of active compounds. Activity of selected compounds tested in the potency screen are shown as a heat map scaled
from ,1 mM (purple) to .10 mM (red) against IKKa, IKKb, IKKe, and TBK1.
doi:10.1371/journal.pone.0041494.g006
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pT (ADpTRYESIDEEAKKK) and IKKb-Tide-A (ADARYESI-
DEEAKKK) were also generated and HPLC purified by the Tufts
University Core Facility. The IkBa (IKK substrate) peptide was
obtained from Upstate. The FL-1 peptide (5-FAM-
AKRRRLSSLRA-COOH) was obtained from Caliper Life
Sciences. For all library screening, recombinant IKKa, IKKb,
IKKe and TBK1 were purchased from Life Technologies
(Invitrogen).
Cell Culture, Transfection, Immunoprecipitations, and
Western Blotting
HEK-293T cells were obtained from ATCC and were grown in
DMEM containing 10% FBS. Transfection was performed by
polyethylenimine. For preparation of recombinant kinases, cells
were lysed in 50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-
100, 1 mM EDTA, 1 mM EGTA, 1 mM b-glycerophosphate,
1 mM PMSF, 1 mM sodium orthovanadate, 1 mg/mL leupeptin,
1 mg/mL pepstatin, and 10 nM Calyculin A.
Design of 4,727 Member Kinase-focused Library
More than 100K compounds were initially reviewed in the form
of SD files from Life Chemicals, ChemDiv, Asinex and Enamine.
These kinase-focused libraries were designed by their respective
vendors using one or more of the following approaches: 1)
searching virtual and physical general purpose libraries for
compounds similar to known kinase inhibitors, 2) selecting or
synthesizing compounds having a hinge-binding motif, e.g.
heterocycles with a high likelihood to bind the kinase hinge motif
conserved in nearly every kinase-small molecule X-ray structure,
and 3) structure- or ligand-based virtual screening on represen-
tative kinase structures. Following an analysis of each vendor’s
library, the UNC CICBDD acquired 4,727 compounds (from all
four vendors) that all were unique and ‘‘rule of five’’ compliant
[33].
High-throughput Screen for TBK1, IKKe, IKKa and IKKb
Inhibitors
5-FAM-labeled TBK1-Tide for library screening was generated
in the High-Throughput Peptide Synthesis and Arrays Core
Facility at University of North Carolina at Chapel Hill. The 1,280
compound Library of Pharmaceutically Active Compounds
(Sigma) and the UNC CICBDD 4,727 compound kinase-focused
library were evaluated for their ability to inhibit phosphorylation
of 5-FAM-TBK1-Tide (TBK1, IKKe, IKKb) or FL-1 (IKKa)
using the MCE EZreader system from PerkinElmer.
In vitro Kinase Assays
Kinase buffer contained 50 mM Tris (pH 7.5), 12 mM MgCl2,
1m M b-glycerophosphate, 100 mM ATP, and 10 mCi c-
32P-
ATP/reaction. Reactions were incubated at 30uC for 1h.
Recombinant GST-TBK1 and GST-TBK1 K38A used in the
positional scanning peptide library assay were generated as
described above and the assay was performed as described
previously [27,28]. MCE assay buffer contained 50 mM Hepes
(pH 7.4), 0.01% Triton X-100, 10 mM MgCl2, 1 mM DTT,
0.01% BSA and ATP at the determined Km (4.7 mM for IKKe,
7.5 mM for TBK1, 134 mM for IKKa, and 2 mM for IKKb).
IKKe reactions were incubated for 2 hours at room temperature
and TBK1, IKKa, and IKKb reactions were incubated for 6
hours at room temperature.
Supporting Information
Figure S1 Selectivity values for TBK1. Following the PSPL
assay, relative affinities for each amino acid at each position
relative to the phosphorylation site were calculated.
(PDF)
Figure S2 Comparison of duplicate compound assay
values. A–B) The LOPAC library was screened in duplicate at
10 mM in a single concentration format against enzymatic
reactions of A) TBK1 and B) IKKe. Results from the first
determination are shown on the horizontal axis (Result 1) and the
second determination is shown on the vertical axis (Result 2).
(PDF)
Figure S3 ATP Km determination for IKKa and IKKb.
Enzymatic reactions of A) IKKa and B) IKKb were incubated at
room temperature with 10 ATP concentrations varying from
Figure 7. Compounds showing the most efficient inhibition of
TBK1. IC50 values of the five most effective TBK1 inhibitors against each
IKK family member are indicated (mM).
doi:10.1371/journal.pone.0041494.g007
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sampled on the Caliper EZReader system at 9.35 minute intervals
over a 3 hour period. Percent conversions were calculated from
relative heights of product and substrate peaks and used to
calculate velocity and ATP Km in Graph Pad Prism.
(PDF)
Table S1 Most active compounds from the LOPAC set.
Values represent percent inhibition of the listed kinase isoform
when treated with the indicated inhibitor at a concentration of
10 mM after 2 hours (at completion of the assay as described in the
text).
(XLSX)
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